Bank of Montreal Can Has $211.43 Million Holdings in Danaher Co. (NYSE:DHR)

Bank of Montreal Can increased its holdings in shares of Danaher Co. (NYSE:DHR) by 3.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 806,470 shares of the conglomerate’s stock after buying an additional 27,970 shares during the quarter. Bank of Montreal Can owned 0.11% of Danaher worth $211,432,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in DHR. Gilbert & Cook Inc. increased its holdings in Danaher by 4.9% during the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after purchasing an additional 86 shares in the last quarter. Accretive Wealth Partners LLC grew its holdings in shares of Danaher by 12.9% in the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after acquiring an additional 414 shares in the last quarter. Gryphon Financial Partners LLC grew its holdings in shares of Danaher by 19.1% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after acquiring an additional 468 shares in the last quarter. TrinityPoint Wealth LLC grew its holdings in shares of Danaher by 12.4% in the 4th quarter. TrinityPoint Wealth LLC now owns 1,469 shares of the conglomerate’s stock valued at $340,000 after acquiring an additional 162 shares in the last quarter. Finally, Congress Wealth Management LLC DE grew its holdings in shares of Danaher by 34.7% in the 4th quarter. Congress Wealth Management LLC DE now owns 5,269 shares of the conglomerate’s stock valued at $1,219,000 after acquiring an additional 1,356 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 in the last quarter. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $273.19 on Tuesday. The stock has a market cap of $202.35 billion, a price-to-earnings ratio of 46.30, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company’s fifty day moving average is $268.16 and its 200 day moving average is $257.32.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business earned $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. Sell-side analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DHR. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Stifel Nicolaus raised their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Barclays raised their target price on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird raised their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.